5-Fluorouracil altered morphology and inhibited growth of Candida albicans [3]

Journal of Clinical Microbiology

Volumn 43, Issue 12, 2005, Pages 6215-6216

  Kesavan, Chandrasekhar ^a   Joyce, Antony George ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

CANDIDA ALBICANS; DNA SYNTHESIS INHIBITION; DRUG EFFECT; FUNGUS GROWTH; FUNGUS ISOLATION; INTRON; LETTER; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RNA SPLICING; RNA TRANSCRIPTION;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CULTURE MEDIA; FLUOROURACIL; HUMANS; MICROBIAL SENSITIVITY TESTS;

CANDIDA ALBICANS; FUNGI;

EID: 30744433912     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.12.6215-6216.2005     Document Type: Letter

References (5)

1. Chandrasekar, K., J. H. Shyla, and R. Malathi. 2000. Can antitumor platinum compounds be effective against Candida albicans? A screening assay using disk diffusion method. J. Clin. Microbiol. 38:3905.
2. De Chaisemartin, L., and M. A. Loriot. 2005. Pharmacogenetics of anticancer drugs. Pathol. Biol. (Paris) 53:116-124.
3. DiNubile, Mark J., Darcy Hille, Carole A. Sable, and Nicholas A. Kartsonis. 2005. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J. Infect. 50:443-449.
4. Disney, M. D., J. L. Childs, and D. H. Turner. 2004. Hoechst 33258 selectively inhibits group I intron self-splicing by affecting RNA folding. Chem. Biochem. 55:1647-1652.
5. Fromtling, R. A. 1998. Human mycoses and current antifungal therapy. Drug News Perspect. 11:185-191.